As of today (2024-05-24), RemeGen Co's share price is HK$25.70.
RemeGen Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.04. Hence, RemeGen Co's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for RemeGen Co's Price-to-Free-Cash-Flow or its related term are showing as below:
HKSE:09995's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.68 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -12.90% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -53.10% per year.
During the past 6 years, RemeGen Co's highest 3-Year average Free Cash Flow per Share Growth Rate was -12.90% per year. The lowest was -73.80% per year. And the median was -20.90% per year.
RemeGen Co Price-to-Free-Cash-Flow Historical Data
The historical data trend for RemeGen Co's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RemeGen Co's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, RemeGen Co's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Price-to-Free-Cash-Flow falls into.
RemeGen Co Price-to-Free-Cash-Flow Calculation
RemeGen Co's Price-to-Free-Cash-Flow ratio for today is calculated as
RemeGen Co's Share Price of today is HK$25.70. RemeGen Co's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
RemeGen Co (HKSE:09995) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
RemeGen Co Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of RemeGen Co's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09995 has been successfully added to your 